![Raju Mohan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Raju Mohan
Gründer bei VENTYX BIOSCIENCES, INC.
Vermögen: 8 Mio $ am 31.05.2024
Profil
Raju S.
Mohan is the founder of Zomagen Biosciences Ltd.
(founded in 2018), Ventyx Biosciences, Inc. (founded in 2018), Vimalan Biosciences, Inc. (founded in 2017), Akarna Therapeutics Ltd.
(founded in 2014), Oppilan Pharma Ltd.
(founded in 2015), and Escalier Biosciences BV (founded in 2016).
Dr. Mohan's current job is as a Partner & Senior Advisor at New Science Ventures LLC (since 2017).
Dr. Mohan's former jobs include being the Vice President & Head-San Diego at Exelixis, Inc. (2006-2011) and the Vice President-Chemistry at X-Ceptor Therapeutics, Inc. (2004-2006).
Dr. Mohan's education includes a graduate degree from the Indian Institute of Technology Bombay and a doctorate degree from the University of Illinois At Urbana–Champaign.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
VENTYX BIOSCIENCES, INC.
2,38% | 10.06.2024 | 1 675 028 ( 2,38% ) | 8 Mio $ | 31.05.2024 |
Aktive Positionen von Raju Mohan
Unternehmen | Position | Beginn |
---|---|---|
VENTYX BIOSCIENCES, INC. | Gründer | 01.11.2018 |
Escalier Biosciences BV
![]() Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Gründer | 01.01.2016 |
New Science Ventures LLC
![]() New Science Ventures LLC Investment ManagersFinance New Science Ventures LLC (New Science Ventures) is a venture capital firm founded in 2004 by Somasundaram Subramaniam and Tom J A Lavin. The firm is headquartered in Greenwich, Connecticut with additional office in London. | Private Equity Investor | 01.01.2017 |
Vimalan Biosciences, Inc. | Gründer | 01.10.2017 |
Ehemalige bekannte Positionen von Raju Mohan
Unternehmen | Position | Ende |
---|---|---|
Zomagen Biosciences Ltd. | Gründer | 01.02.2021 |
Oppilan Pharma Ltd.
![]() Oppilan Pharma Ltd. BiotechnologyHealth Technology Oppilan Pharma Ltd. operates as a biotechnology company. The company is headquartered in Cambridge, the United Kingdom. | Gründer | 01.02.2021 |
Akarna Therapeutics Ltd.
![]() Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Gründer | 01.09.2016 |
EXELIXIS, INC. | Corporate Officer/Principal | 01.01.2011 |
X-Ceptor Therapeutics, Inc.
![]() X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01.01.2006 |
Ausbildung von Raju Mohan
Indian Institute of Technology Bombay | Graduate Degree |
University of Illinois At Urbana–Champaign | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
VENTYX BIOSCIENCES, INC. | Health Technology |
EXELIXIS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Akarna Therapeutics Ltd.
![]() Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Oppilan Pharma Ltd.
![]() Oppilan Pharma Ltd. BiotechnologyHealth Technology Oppilan Pharma Ltd. operates as a biotechnology company. The company is headquartered in Cambridge, the United Kingdom. | Health Technology |
Escalier Biosciences BV
![]() Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Health Technology |
New Science Ventures LLC
![]() New Science Ventures LLC Investment ManagersFinance New Science Ventures LLC (New Science Ventures) is a venture capital firm founded in 2004 by Somasundaram Subramaniam and Tom J A Lavin. The firm is headquartered in Greenwich, Connecticut with additional office in London. | Finance |
Vimalan Biosciences, Inc. | |
Zomagen Biosciences Ltd. | |
X-Ceptor Therapeutics, Inc.
![]() X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |